Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD, Inc. (NSPR) is a medical device company whose news flow centers on its CGuard® Prime carotid stent system and proprietary MicroNet™ mesh technology for stroke prevention. Company press releases and SEC filings describe InspireMD as the developer of CGuard® Prime for the treatment of carotid artery stenosis, with a focus on making its products a standard approach in carotid stenting.
News about InspireMD often covers clinical milestones and peer-reviewed publications. For example, the company announced that results from its C-GUARDIANS pivotal trial of the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology, with data showing low rates of disabling stroke or myocardial infarction through 30 days and low ipsilateral stroke rates through one year. InspireMD has also highlighted external clinical evidence such as the CREST-2 study in the New England Journal of Medicine, which it views as supportive of carotid artery stenting combined with medical therapy.
Investors following NSPR can also expect updates on regulatory and commercial developments. Recent filings report FDA PMA approval for the CGuard Prime Carotid Stent System in the United States and subsequent announcements of a U.S. commercial launch. Quarterly earnings releases describe the impact of CGuard Prime on revenue and provide commentary on procedure volumes and expansion of the company’s commercial team.
Additional news items include capital-raising transactions, such as private placements and warrant exercises, as well as changes in board composition and senior medical leadership. Together, these updates give readers insight into InspireMD’s clinical progress, regulatory status, commercialization efforts, and corporate governance. This page aggregates such NSPR news so readers can review the company’s key announcements in one place.
InspireMD (NYSE American: NSPR) has appointed Dr. Chris Metzger as the principal investigator for its upcoming FDA registration trial for the CGuard™ Embolic Prevention System (EPS). Dr. Metzger brings extensive clinical trial experience and is expected to provide significant leadership for the study. The CGuard EPS aims to address stroke prevention related to carotid artery disease, leveraging its unique MicroNet technology. InspireMD's CEO, Marvin Slosman, emphasized the importance of Dr. Metzger's role in ensuring the trial's success, which could potentially establish CGuard as a new standard in carotid artery management.
InspireMD reported the successful closing of an upsized public offering, generating approximately $20.7 million in gross proceeds. The offering included 29,032,258 Units priced at $0.62 each, each consisting of one share of Common Stock and a Series G Warrant. Furthermore, an over-allotment option led to the purchase of an additional 4,354,838 Units. The offering, managed by A.G.P./Alliance Global Partners, was registered with the SEC. Funds raised will be critical for further business development in the competitive medical device sector.
InspireMD announced an upsized underwritten public offering of securities to raise $18 million, which could increase to $20.7 million if underwriters exercise their additional purchase option. The offering includes 29,032,258 Units priced at $0.62 each, comprising one share of Common Stock and one Series G Warrant. The offering is expected to close around February 8, 2021. A.G.P./Alliance Global Partners serves as the sole book-running manager. This follows the SEC's approval of the registration statement on Form S-1.
InspireMD has announced a partnership with Chinese distributors, including Shanghai Micro Medical, to market its CGuard™ Embolic Prevention System in mainland China. This agreement includes conducting registration trials for regulatory approval and grants an eight-year exclusive distribution right in China. Additionally, QIDI Asia Medical will invest $900,000 in a private placement of the company's stock. This move positions InspireMD to expand in a rapidly growing market, with stroke being a significant health issue in China.
InspireMD (NYSE American: NSPR) announced multiple presentations regarding the CGuard™ Embolic Prevention System at the Leipzig Interventional Congress from January 25-29, 2021. Key presentations include the IRONGUARD 2 study results and a live demonstration of CGuard implantation. The company emphasizes the advantages of CGuard over first-generation stents, citing its MicroNet technology as a potential new standard for carotid artery disease management. InspireMD aims to enhance global awareness and acceptance of CGuard for improved patient outcomes.
InspireMD, developer of the CGuard™ Embolic Prevention System (EPS), announced its third quarter 2020 results, marking a return to pre-COVID revenue levels with $980,000, up 4.4% from the previous year. The FDA approved its Investigational Device Exemption to initiate a pivotal study for CGuard EPS. Gross profit increased by 132.8% to $298,000, while total operating expenses rose 17.3% to $2,493,000. Despite a net loss of $2,233,000, a decrease from last year's loss, InspireMD remains optimistic about its growth strategy in endovascular carotid artery stent procedures and expanding into international markets.
TEL AVIV, Israel, Nov. 3, 2020 – InspireMD (NYSE American: NSPR) appointed Andrea Tommasoli as senior vice president of global sales and marketing. Tommasoli brings over 20 years of medical technology experience, previously serving in leadership roles at Integra Life Sciences and St. Jude Medical-Abbott. His expertise is expected to enhance InspireMD's sales strategy. The company also granted him 271,534 shares of restricted stock and options for 90,511 shares as part of his inducement package. The awards have a ten-year term and will vest over three years, contingent on continued employment.
InspireMD, Inc. (NYSE American: NSPR) announced the appointment of Andrea Tommasoli as senior vice president of global sales and marketing, effective immediately. With over 20 years of experience in medical technology, Tommasoli previously held leadership roles at Integra Life Sciences and St. Jude Medical-Abbott. He will oversee all sales and marketing efforts for InspireMD’s innovative CGuard™ Embolic Prevention System, aimed at improving stroke prevention in carotid artery disease. Additionally, Tommasoli received inducement awards including 271,534 shares of restricted stock and options to purchase 90,511 shares at an exercise price of $0.35.
InspireMD, a developer of the CGuard™ Embolic Prevention System, will report its fiscal third quarter 2020 financial results on November 9, 2020, before market opening. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss the results and corporate updates. Registered participants will receive direct dial-in numbers, while others can call in using provided domestic and international numbers. The conference call will be available via live webcast and replay links. InspireMD aims to establish its MicroNet® technology as the industry standard for carotid stenting.
InspireMD (NYSE American: NSPR) announced the appointment of Dr. Gary Roubin to its Board of Directors. Dr. Roubin, an esteemed interventional cardiologist, is recognized for his work in carotid stenting and contributed to the development of coronary stents. His expertise is expected to enhance InspireMD's global expansion plans for its CGuard Embolic Prevention System, which has shown superior clinical outcomes. CEO Marvin Slosman highlighted Dr. Roubin's appointment as a vote of confidence in the company's potential and technology.
FAQ
What is the current stock price of Inspiremd (NSPR)?
What is the market cap of Inspiremd (NSPR)?
